Sanjay Chanda

Dr. Sanjay Chanda brings over twenty-five years of experience in drug development, including product development, regulatory affairs, and product registration to AN2 Therapeutics, where he is the Chief Development Officer. Previously, Dr. Chanda served as Chief Development Officer at Tioma Therapeutics, and co-founded Auration, Inc., an early-stage pharmaceutical company focused on treating chronic hearing loss in humans. Prior to his CDO role at Tioma Therapeutics, Dr. Chanda was the Senior Vice President of Drug Development at Anacor Pharmaceuticals (acquired by Pfizer). At Anacor, he was responsible for all aspects of CMC and Preclinical Safety and played key leadership roles in the development and approvals of KERYDIN® for the treatment of onychomycosis and EUCRISA® for the treatment of atopic dermatitis (eczema). He has held leadership positions at NeurogesX, Inc., Cerus Corporation, and PPD-Development. Dr. Chanda has over thirty publications in various peer-reviewed journals. He received his Ph.D. in Pharmacology/Toxicology at Northeast Louisiana University and completed postdoctoral fellowships at the University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina.